Identifier |
20210221_nanos_journalclub1_06-abstract |
Title |
Treatment of Intracranial Hypertension: New Options or Not? |
Creator |
Julie Falardeau, MD |
Affiliation |
Oregon Health and Science University, Portland, OR |
Subject |
Diopathic Intracranial Hypertension; Weight Loss; Carbonic Anhydrase Inhibitor; Glucagon-like Peptide 1 Receptor Agonist; 11b-hydroxysteroid Dehydrogenase Type 1 |
Description |
Idiopathic intracranial hypertension (IIH) is characterized by elevation of intracranial pressure (ICP) without; an identifiable cause. Over the years, a number of varied treatments have been suggested with the; ultimate goals to preserve vision and alleviate symptoms, especially headache. There are currently no; established guidelines to standardize the treatment of IIH. In 2015, the Cochrane review concluded that; there is insufficient evidence on the best therapeutic strategies. Traditionally, the treatment of IIH has; included weight loss, medications, and surgical interventions when rapid or progressive vision loss occurs; despite optimal medical therapy. |
Date |
2021-02 |
Language |
eng |
Format |
application/pdf |
Type |
Text |
Source |
2021 North American Neuro-Ophthalmology Society Annual Meeting |
Relation is Part of |
NANOS Annual Meeting 2021: Journal Club: What You Need to Know Now! |
Collection |
Neuro-Ophthalmology Virtual Education Library: NANOS Annual Meeting Collection: https://novel.utah.edu/collection/nanos-annual-meeting-collection/ |
Publisher |
North American Neuro-Ophthalmology Society |
Holding Institution |
Spencer S. Eccles Health Sciences Library, University of Utah |
Rights Management |
Copyright 2021. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright |
ARK |
ark:/87278/s6sj7jdt |
Setname |
ehsl_novel_nam |
ID |
1694263 |
Reference URL |
https://collections.lib.utah.edu/ark:/87278/s6sj7jdt |